Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations.

Elio AdibKatarzyna KlonowskaKrinio GiannikouKhanh T DoSolida Pruitt-ThompsonKetki BhushanMatthew I MilsteinJennifer HedglinKatherine E KargusLynette M ShollJunko TsujiDavid M HymanAnne SiskGeoffrey I ShapiroHebert Alberto VargasJames J HardingMartin H VossGopa IyerDavid J Kwiatkowski

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Everolimus therapy had a disappointing ORR (7%) in this pan-cancer, mutation-selected, basket study.See related commentary by Kato and Cohen, p. 3807.

Keyphrases

phase ii
clinical trial
papillary thyroid
open label
squamous cell
cell proliferation
phase iii
squamous cell carcinoma
childhood cancer
lymph node metastasis
stem cells
placebo controlled